EP3585444A1 - Gewebe-targetingkomplex - Google Patents
Gewebe-targetingkomplexInfo
- Publication number
- EP3585444A1 EP3585444A1 EP18705171.9A EP18705171A EP3585444A1 EP 3585444 A1 EP3585444 A1 EP 3585444A1 EP 18705171 A EP18705171 A EP 18705171A EP 3585444 A1 EP3585444 A1 EP 3585444A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tissue
- targeting
- complex according
- targeting complex
- chromophore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 claims abstract description 65
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000003277 amino group Chemical group 0.000 claims abstract description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
- 239000012528 membrane Substances 0.000 claims description 41
- 229920000642 polymer Polymers 0.000 claims description 34
- 238000010186 staining Methods 0.000 claims description 30
- 125000005647 linker group Chemical group 0.000 claims description 19
- -1 halide ion Chemical class 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 13
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 9
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 2
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000975 dye Substances 0.000 description 60
- 238000005259 measurement Methods 0.000 description 35
- 239000000243 solution Substances 0.000 description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 239000000758 substrate Substances 0.000 description 24
- 238000010521 absorption reaction Methods 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000003786 synthesis reaction Methods 0.000 description 19
- 150000004056 anthraquinones Chemical class 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 239000001000 anthraquinone dye Substances 0.000 description 12
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 12
- 229960004657 indocyanine green Drugs 0.000 description 12
- 210000001525 retina Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- MNYDPUKNBLNTJQ-UHFFFAOYSA-N 1,4-bis[2-(dimethylamino)propylamino]anthracene-9,10-dione Chemical compound CC(CNc1ccc(NCC(C)N(C)C)c2C(=O)c3ccccc3C(=O)c12)N(C)C MNYDPUKNBLNTJQ-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 10
- DTNCXQHDOJRTCD-UHFFFAOYSA-N 1,4-difluoroanthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(F)=CC=C2F DTNCXQHDOJRTCD-UHFFFAOYSA-N 0.000 description 9
- 239000003086 colorant Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- LJNGZHUTSGBBNN-UHFFFAOYSA-N 1,4-difluoro-6-methylanthracene-9,10-dione Chemical compound Cc1ccc2C(=O)c3c(F)ccc(F)c3C(=O)c2c1 LJNGZHUTSGBBNN-UHFFFAOYSA-N 0.000 description 8
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 8
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- SWVGZFQJXVPIKM-UHFFFAOYSA-N n,n-bis(methylamino)propan-1-amine Chemical compound CCCN(NC)NC SWVGZFQJXVPIKM-UHFFFAOYSA-N 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- MYMSJFSOOQERIO-UHFFFAOYSA-N 1-bromodecane Chemical compound CCCCCCCCCCBr MYMSJFSOOQERIO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 238000004040 coloring Methods 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 229910003460 diamond Inorganic materials 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- QUGUFLJIAFISSW-UHFFFAOYSA-N 1,4-difluorobenzene Chemical compound FC1=CC=C(F)C=C1 QUGUFLJIAFISSW-UHFFFAOYSA-N 0.000 description 5
- VVVJTDVXIMBTKT-UHFFFAOYSA-N 5,8-difluoro-9,10-dioxoanthracene-2-carboxylic acid Chemical compound OC(=O)c1ccc2C(=O)c3c(F)ccc(F)c3C(=O)c2c1 VVVJTDVXIMBTKT-UHFFFAOYSA-N 0.000 description 5
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229910052731 fluorine Inorganic materials 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- RZVHIXYEVGDQDX-UHFFFAOYSA-N 9,10-anthraquinone Chemical group C1=CC=C2C(=O)C3=CC=CC=C3C(=O)C2=C1 RZVHIXYEVGDQDX-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000004127 vitreous body Anatomy 0.000 description 4
- XNBMXFXYEZUSPH-UHFFFAOYSA-N 1,4-bis[3-(dimethylamino)propylamino]-6-methylanthracene-9,10-dione Chemical compound CN(C)CCCNc1ccc(NCCCN(C)C)c2C(=O)c3cc(C)ccc3C(=O)c12 XNBMXFXYEZUSPH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000940468 Drosophila melanogaster COP9 signalosome complex subunit 2 Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 101150118795 UCH2 gene Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- FBMQNRKSAWNXBT-UHFFFAOYSA-N 1,4-diaminoanthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C(N)=CC=C2N FBMQNRKSAWNXBT-UHFFFAOYSA-N 0.000 description 2
- FWEYMISYVXOXDC-UHFFFAOYSA-N 1-[3-(dimethylamino)propylamino]-4-fluoroanthracene-9,10-dione Chemical compound CN(C)CCCNc1ccc(F)c2C(=O)c3ccccc3C(=O)c12 FWEYMISYVXOXDC-UHFFFAOYSA-N 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 2
- VMKOFRJSULQZRM-UHFFFAOYSA-N 1-bromooctane Chemical compound CCCCCCCCBr VMKOFRJSULQZRM-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 239000011903 deuterated solvents Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- RGALIJDPFBKIGO-UHFFFAOYSA-N 1,2-difluoroanthracene-9,10-dione Chemical compound C1=CC=C2C(=O)C3=C(F)C(F)=CC=C3C(=O)C2=C1 RGALIJDPFBKIGO-UHFFFAOYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- KHUFHLFHOQVFGB-UHFFFAOYSA-N 1-aminoanthracene-9,10-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2N KHUFHLFHOQVFGB-UHFFFAOYSA-N 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- IGNPXHJOMLPZOL-UHFFFAOYSA-N 2-methylnonan-2-amine Chemical compound CCCCCCCC(C)(C)N IGNPXHJOMLPZOL-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- DIHWEKVWWQSJMQ-UHFFFAOYSA-N 5,8-bis[3-(dimethylamino)propylamino]-9,10-dioxoanthracene-2-carboxylic acid Chemical compound CN(CCCNC1=C2C(C=3C=CC(=CC=3C(C2=C(C=C1)NCCCN(C)C)=O)C(=O)O)=O)C DIHWEKVWWQSJMQ-UHFFFAOYSA-N 0.000 description 1
- ZOXBWJMCXHTKNU-UHFFFAOYSA-N 5-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=C2C(=O)OC(=O)C2=C1 ZOXBWJMCXHTKNU-UHFFFAOYSA-N 0.000 description 1
- CDWGDLKZKCYUFO-UHFFFAOYSA-N 6-(trifluoromethyl)-1h-indole-2-carboxylic acid Chemical compound C1=C(C(F)(F)F)C=C2NC(C(=O)O)=CC2=C1 CDWGDLKZKCYUFO-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- RXVLJEVMGMONLC-UHFFFAOYSA-N C1=CC=CC=2C(C3=CC=CC=C3C(C12)=O)=O.[N] Chemical group C1=CC=CC=2C(C3=CC=CC=C3C(C12)=O)=O.[N] RXVLJEVMGMONLC-UHFFFAOYSA-N 0.000 description 1
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 1
- CDAYUNBVZVAQOP-UHFFFAOYSA-N CCCCCCCCCC(CCCNC(C(C(C1=CC=CC=C11)=O)=C2C1=O)=CC=C2NCCCC(CCCCCCCCC)N(C)C)N(C)C.Br Chemical compound CCCCCCCCCC(CCCNC(C(C(C1=CC=CC=C11)=O)=C2C1=O)=CC=C2NCCCC(CCCCCCCCC)N(C)C)N(C)C.Br CDAYUNBVZVAQOP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- VVOLVFOSOPJKED-UHFFFAOYSA-N copper phthalocyanine Chemical compound [Cu].N=1C2=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC(C3=CC=CC=C33)=NC3=NC=1C1=CC=CC=C12 VVOLVFOSOPJKED-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- XKBGEWXEAPTVCK-UHFFFAOYSA-M methyltrioctylammonium chloride Chemical compound [Cl-].CCCCCCCC[N+](C)(CCCCCCCC)CCCCCCCC XKBGEWXEAPTVCK-UHFFFAOYSA-M 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- OKPYIWASQZGASP-UHFFFAOYSA-N n-(2-hydroxypropyl)-2-methylprop-2-enamide Chemical class CC(O)CNC(=O)C(C)=C OKPYIWASQZGASP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- DHAHKSQXIXFZJB-UHFFFAOYSA-O patent blue V Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=C(O)C=1)S(O)(=O)=O)S(O)(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 DHAHKSQXIXFZJB-UHFFFAOYSA-O 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 239000004177 patent blue V Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 229920001562 poly(N-(2-hydroxypropyl)methacrylamide) Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- SRPWOOOHEPICQU-UHFFFAOYSA-N trimellitic anhydride Chemical compound OC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 SRPWOOOHEPICQU-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
Definitions
- the present invention relates to a tissue-targeting complex and its use in particular in ophthalmology.
- a stain suitable for staining should bind as selectively as possible to a particular type of tissue or membrane so that the binding of this stain is indicative of the presence or location.
- a dye suitable for this purpose must be generally compatible, and should have a color that stands out well from the environment in which it is intended to be dyed.
- dyes are used to stain membranes which are then surgically removed.
- a dye used for this purpose should be water-soluble, as solvents in such a sensitive organ as the eye should be avoided, should have such a color that it differs well from the environment, should be easily removable and of course not irritate the eye or harm.
- all these dyes have hitherto disadvantages to be overcome with the present invention.
- a vitrectomy is often indicated, ie an intervention in which the vitreous body or parts thereof are removed to then remove the membrana limitans interna or optionally formed epiretinal membranes from the retina inside the eye in order to induce healing processes thereby, or to prevent further damage to the retina.
- the corresponding membrane is withdrawn from the retina with conventional surgical instruments and it is very important for the surgeon to be able to distinguish between the membrane to be withdrawn and the underlying retina so as not to damage the retina during the procedure.
- the retina consists of several layers with individual functions.
- the choroid carries most of the photoreceptors and is also responsible for the adequate blood supply.
- the Membrana limitans interna is the basal membrane of Müller cells, ie an extracellular membrane that separates the vitreous body from the retina and thus represents the inner delineation of the retina. It is not only connected to the processes of the Müller cells, but also via fibrils with the vitreous humor. This compound is characterized by adhesions of collagen fibers of the vitreous to the ILM.
- the ILM consists of different types of glycoproteins and collagen. Their layer thickness reaches up to 2.5 ⁇ . This boundary layer is often affected by diseases that limit vision and can be treated by surgical procedures.
- epiretinal membranes can form on the retina, which can arise without cause or arise from previous diseases or interventions. These membranes can contract, resulting in retinal deformation and therefore vision impairment. Such deformations that exert a pull on the retina or the macula must therefore be removed.
- dyes for this purpose are e.g. Brilliant blue G, brilliant blue R, patent blue V and trypan blue as well as indocyanine green.
- the dyes mentioned show either a toxic effect or too low staining power for the surgical procedure.
- the invention relates to a tissue-targeting complex, the at least one
- Targeting Element [ALQ + -alk B "], where A is an anchor group, L is a linker, Q + is a quaternary ammonium group B" is an ophthalmically acceptable counterion and Alk represents an alkyl chain having a chain length of 4 to 12 carbon atoms; comprises at least one chromophore and / or at least one carrier molecule.
- Tissue or for the staining of ocular tissue, such as membranes suitable complexes can be formed by using a complex having at least two elements, namely at least one targeting element and at least one chromophore and / or at least one carrier molecule.
- the tissue targeting complex of the invention may be e.g. a chromophore and as a third component having a carrier molecule.
- the advantageous properties are achieved by providing separate units for interaction with a desired environment and for dyeing. This makes it possible to provide a chromophore which has a desired hue, but which is not selective for a tissue to be stained, in such a form that the corresponding tissue can be selectively stained.
- composition of parts of molecules which, independently of one another, assume different functions
- tissue-targeting complex of the present invention is a complex that comprises a targeting moiety and a coloring or functional moiety and then interacts there with target tissue and, for example, either directly or after irradiation with appropriate wavelength light to the eye visibly colors the target area.
- chromophore refers to a molecule, element, moiety, or group that can produce a color, either directly or by irradiation with light of appropriate wavelength. The color produced is one that is visible to the eye and thus in a range of 380 to 780 nm.
- physiological "acceptable” or “ophthalmologically acceptable” refer to substances, substances, materials, etc., which do not damage the organism to which a composition containing this substance, material or substance is administered and are adapted to the conditions prevailing there
- ophthalmologically acceptable means that the corresponding substance does not irritate or damage the eye, which is particularly sensitive.
- carrier molecule refers to any type of molecule capable of carrying elements such as targeting elements or chromophores of the present invention.
- Carrying in this context means for an element any kind of fixation on a carrier molecule which can take place via covalent bonding or interactions, for example by adsorption.
- elements are covalently bonded to a carrier molecule.
- the carrier molecule can be any form suitable for the function
- the carrier molecule may be in the form of chains, coils, nanoparticles or microparticles or other forms customary for inert carrier molecules.
- linker unit refers to a
- a linker unit can be any molecule that connects two units.
- a linker molecule has a suitable length for the particular purpose, the unit should not be too long, so as not to remove the elements to be connected too far apart. In general, the linker unit contributes neither charge nor function.
- a "quaternary ammonium ion” is a group that is positively charged and includes a nitrogen and four groups attached to it.
- water-soluble and water-compatible are used interchangeably in the context of polymers or the tissue-targeting complex according to the invention. Since the large-molecule dispersion and solution transitions, such as tissue-targeting complexes of the invention containing polymers, can often not be detected, a water-soluble tissue-targeting complex is understood to be one which mixes with water and can does not settle.
- target area refers to the area in which binding or staining is to be achieved. As a rule, it is the ILM and / or epiretinal membranes for the present invention.
- interacting when used in the context of the selectivity of the targeting element refers to any type of interaction between the targeting element and the membrane that results in the targeting element and thus the targeting element complex according to the invention remains at the point at which the interaction takes place. Any kind of physical interaction comes into consideration as long as the complex is held in the place where it is to be effective.
- eye membranes refers to those membranes which are present in the eye, in particular epiretinal membranes and ILM.
- the complex according to the invention comprises at least one targeting element which leads the complex directly to the target region which is to be stained and in which the dye and / or the carrier molecule should be adsorbed, bound or otherwise interacting for the desired duration.
- a targeting element is therefore an element that interacts specifically with a target area.
- This structural element [ALQ + Alk B " ] consists of an anchor group, a linker, a quaternary ammonium group and an alkyl chain with a length of 4 to 12.
- the anchor group is formed by a heteroatom which is N, O, S, P or may be another heteroatom capable of bonding, or a functional group, and has the function of binding to a chromophore or a carrier molecule, more particularly, the heteroatom may be N, S, or O.
- the functional group consideration is given to those groups which readily bind such as alcohol, carbonyl, carboxyl radicals, etc.
- the anchor group is connected via a linker with a quaternary ammonium group.
- the linker molecule is a molecule that links the anchor group to the quaternary ammonium group, maintains both groups at a predetermined distance, and also adds flexibility. Any molecule that contributes a chain length in the range of 1 to 10 atoms, preferably 1 to 8, in particular 1 to 6 atoms and fulfills the function described, is suitable here. Particularly suitable is an alkyl chain having 1 to 6, preferably 2 to 4 carbon atoms proved.
- the quaternary ammonium group Q + which is bound on the one hand via the linker to the anchor group and on the other side carries an alkyl chain, has two more substituents. These two substituents are not critical as long as they are neutral for the function of guiding the molecule to a target region, ie, do not interfere with the desired function. Suitable are, for example, C 1 -C 4 -alkyl groups. Preferably, the two substituents are independently H or methyl.
- a counter ion B is present for the quaternary ammonium group, the counterion is not critical per se, and therefore any physiologically or ophthalmologically suitable counterion can be used, preference being given to a halide ion, for example chloride ion or bromide ion, or hydrogen phosphate or hydrogen sulfation used as a counterion.
- the third part of the targeting element of the invention is an alkyl chain having a chain length of 4 to 12 carbon atoms, preferably 6 to 10 carbon atoms. It has been found that an alkyl chain attached to the quaternary ammonium group contributes to the interaction with the ILM. If the alkyl chain has less than 4 carbon atoms, the selective bond is no longer achieved. If the chain length exceeds 12 carbon atoms, there are problems with the water solubility of the complex of the invention. Furthermore, it has been found that it is not advantageous for the alkyl chain to contain unsaturated bonds as this limits the flexibility of the chain. Branched alkyl chains are also suitable as long as the branches do not affect flexibility. If a branched alkyl group is used, a critical factor is the length of the longest linear chain, referred to herein as chain length. As a rule, the chain has methyl groups as branches.
- the targeting element may be attached via the anchor group to either a chromophore or a carrier molecule or both, and as a specific binding element, which in turn is linked via a linker, carries a quaternary ammonium ion with a flexible alkyl chain essential for interaction with ocular membranes are.
- the targeting element should therefore be bound to a chromophore and / or a carrier molecule such that the quaternary group and hydrophobic moiety are accessible for interaction with the target region.
- a second important constituent of the tissue-targeting complex according to the invention is at least one chromophore or at least one carrier molecule.
- the staining complex is intended for staining an ophthalmic membrane, the stain or the chromophore must fulfill the abovementioned requirements, ie it must not be irritating or toxic, must achieve adequate staining and form a water-soluble or water-compatible staining complex.
- chromophore known dyes can be used, as long as they meet the above requirements.
- those dyes are suitable which have a hue in the range of blue to green in order to stand out against the reddish background as much as possible.
- the dye should contribute as much as possible coloring, since the concentration of the dye may be the lower, the stronger the coloration. The lowest possible concentration is desirable in order to use the lowest possible dose, whereby better tolerances are achieved.
- the complex according to the invention also contributes to the fact that the dose must be lower than in the case of other known dyes.
- the amount of dye can be reduced.
- the dye is selectively brought to the desired location and lingers there.
- anthraquinone dyes are well known in the art.
- the coloration can be adjusted by derivatization, so that a desired hue can be achieved by appropriate derivatization.
- other elements such as targeting elements, bridge elements or carrier molecules can be introduced or bound.
- Dyes with total visible absorption can be synthesized by varying the nature of the substituent and its position on the anthraquinone backbone.
- substitutions at positions 1, 4, 5 and 8, ie in the position of the anthraquinone have a strong influence on the absorption of the dye.
- Unsubstituted anthraquinone has an absorption maximum of 405 nm.
- Electron donors cause a bathochromic shift, ie a shift into the longer wavelength range.
- the extinction coefficient is increased, for example in the 1, 4-diaminoanthraquinone to the Three times.
- Substituents at positions 2, 3, 6 and 7, ie a so-called ⁇ -position have less influence on coloring and reactivity. If necessary, these positions can be used for the connection of other elements. Since the color is already changed by the introduction of a functional group, it is also possible to use one of the other ⁇ -positions for the binding of further elements, without restricting the possibilities of coloring.
- anthraquinone dyes are their high stability to thermal influences, chemicals and light.
- the ⁇ -positions of the anthraquinone can thus be selectively derivatized to adjust the desired hue. Furthermore, the anthraquinone skeleton offers the possibility to introduce a targeting element, since sufficient positions are available for derivatization.
- the derivatization per se can be carried out by conventional methods in a relatively simple manner, as described in the examples.
- anthraquinones substituted with amines at the two o positions of one of the two phenyl rings have been found to give a blue color while anthraquinones in which an amino group and a halogen group are attached to the ⁇ -positions of a phenyl ring are more reddish Color area.
- another heteroatom e.g. O or S
- the color also changes.
- the second phenyl ring may be unsubstituted.
- anthraquinones substituted at two ⁇ -positions with substituted amino groups are used as a chromophore contributing to blue color.
- the chromophore is a compound of the formula I
- each of R 10 , R 11 , R 12 and R 13 is independently of one another hydrogen, C 1 -C 4 -alkyl radicals, an anchor group as defined in claim 1 or a Linker molecule is,
- each of R 14 , R 15 , R 16 and R 17 is independently hydrogen, C 1 -C 4 alkyl or a linker moiety.
- anthraquinones which not only have the preferred blue hue but also carry targeting elements having the ability to selectively bind to ocular membranes, ILM and ERM by simultaneously introducing the two amino groups of anthraquinone introduced to achieve the blue color as anchor groups be used of the targeting element.
- the targeting elements do not disturb the staining and the anthraquinone group does not interfere with the specific binding.
- the anthraquinone carries at two ⁇ -positions an amino group which is substituted with a C 1 -C 6 -alkyl group, the other end of the alkyl group not attached to the anthraquinone nitrogen carries a quaternary ammonium ion, to which in turn an alkyl chain is attached.
- This combination of anthraquinone dye and targeting element contributes to both blue staining and ocular membrane interaction. This provides a tissue targeting complex that has many beneficial properties.
- the anthraquinone may be substituted at one to four ⁇ -positions with heteroatom groups, especially amino groups.
- the number of substituents can be used to affect the hue accordingly.
- they may either be both attached to the o-positions of a phenyl group, or each of the two phenyl groups may each have one amino group attached to it.
- the amino group is thus substituted so that it simultaneously represents the targeting element of the complex.
- Substituting the desired hue has further derivatized by a targeting element is introduced at one of the still free positions.
- a targeting element is introduced at one of the still free positions.
- 1, 2, 3 or 4 of the ⁇ -positions of the anthraquinone carry such substituents which affect the hue, e.g. Electron donors, such as alkylamino groups, and one of the remaining positions, e.g. also a ⁇ -position, bound, via the anchor group, the targeting element.
- anthraquinones are water-soluble or water-compatible and can therefore be used in this form for staining ocular membranes.
- the tissue-targeting complex in addition to the at least one targeting element and at least one chromophore still contains a carrier molecule.
- the carrier molecule is chosen to prevent deeper penetration into cells.
- a suitable carrier molecule must be water compatible, must not interfere with the specific binding capacity of the targeting element, and must not be irritating or detrimental to cells. In other words, it is a physiologically or ophthalmologically acceptable polymer. Such polymers are known per se.
- Suitable carrier molecules are those polymers which carry functional groups via which chromophores and / or targeting elements can be bound.
- Any carrier molecule is suitable that is water compatible in the resulting staining complex, does not interfere with the targeting function or staining, and can bind chromophores and / or targeting moieties.
- Suitable are water-compatible polymers such as e.g. Vinyl-derived polymers and copolymers, polyalcohol-derived polymers and copolymers, acrylic-based polymers and copolymers, as well as natural and derivatized polymers, also contemplates peptides or proteins.
- vinyl compound-derived polymers and copolymers there may be mentioned polyvinylamine, polyvinyl alcohol, polyvinylpyrrolidone, and the corresponding copolymers.
- polyalcohol-derived polymers and copolymers examples include polyglycerols, polysaccharides, polydextrins, cyclodextrins, polyethylene glycols, celluloses and cellulose derivatives such as hydroxypropylmethylcellulose, hydroxyethylcellulose, hyaluronic acid and hyaluronic acid derivatives.
- acrylic-based polymers there can be mentioned poly-N- (2-hydroxypropyl) methacrylamides and N- (2-hydroxypropyl) methacrylamides.
- suitable polymers are polyglutamates, lactide and / or glycolide based polymers, e.g. Polylactides also as copolymer, polyglutamates, polyamidoamines and other polymers that meet the above conditions. Mixtures of the polymers mentioned can also be used.
- the size of the carrier molecule can vary widely and is dependent on the particular polymer selected, loading, etc. Polymers having a molecular weight in the range of 900 to 10 million are contemplated. Are suitable Carrier molecules having a molecular weight in a range of 5,000 to 500,000 or 1 million, for example preferably 20,000 to 200,000, in particular 30,000 to 100,000.
- chromophores and / or targeting elements can be attached to polymers having reactive groups. Suitable for this purpose are e.g. Homopolymers or copolymers derived from vinylamines, on the amine groups of which appropriately attacked substituted anthraquinones can be covalently bonded.
- the polymer for a carrier molecule may also be a peptide or protein. Particularly suitable for this embodiment are halo-substituted anthraquinones, i. Anthraquinones bearing a halogen group at the point of attachment. The halogen group should therefore be in the position where attachment to the polymer is desired.
- anthraquinone dyes is that reactive and less reactive positions are available for bonds on both phenyl rings, and that positions with influence on the color (a) and positions without appreciable influence on the color of the resulting molecule ( ⁇ ) are available.
- an anthraquinone derivative which has a targeting element at at least one ⁇ -position and optionally has a binding site for a carrier molecule at a ⁇ -position, e.g. a halogen, such as fluorine or bromine.
- the tissue-targeting complex according to the invention may then, in one embodiment, carry a chromogenic and targeting group at at least one ⁇ -position and be bound to a carrier molecule at a ⁇ -position via a linking group.
- the anthraquinone derivative carries one or two targeting elements on a phenyl ring and is attached to a carrier molecule at a ⁇ -position of the other phenyl ring.
- the function of the carrier molecule is, inter alia, penetration of the
- the support element should be of such size that the complex is not taken up in a cell.
- the polymer must not be so large that it becomes insoluble or is no longer present in dissolved or water-dispersed form.
- the carrier molecule may have any suitable shape. It may be a polymer chain to which chromophores and targeting elements are attached in any order. It may also be branched polymers to whose branches chromophores and / or targeting elements are bound. In another embodiment, the polymer may be in the form of beads having chromophore and / or targeting elements attached to the surface thereof.
- the targeting element may also be bound to the chromophore due to its structure
- the complex is constructed such that are bound to the carrier molecule chromophore units, which in turn are bound targeting elements.
- the number of chromophores and / or targeting elements bound to a carrier molecule depends on the size of the carrier molecule, the type of monomer units, the binding capacity of the targeting element, the coloring capacity of the chromophore or chromophores.
- the skilled person can find out the optimum ratio of carrier molecule / chromophore / targeting element with simple routine experiments.
- the ratio of chromophore units to targeting elements is also not critical and depends e.g. color intensity of the chromophore, affinity of the targeting element, desired hue. It has been found that an excess of targeting elements is often advantageous compared to chromophores.
- a molar ratio of chormophor units to targeting elements in the range of 1:20 to 5: 1, especially 1:10 to 2: 1, is considered suitable.
- chromophore usually, only one type of chromophore is used for the tissue targeting complex of the invention. However, it is also possible to bind to a carrier molecule different chromophores or to use a mixture of carrier molecules, each carrying different chromophores. It is essential only to achieve the desired color to then stain ocular membranes.
- tissue-targeting complex also makes it possible to provide a colorant which appears in different colors, depending on the light source used.
- tissue-targeting complexes of the invention having different chromophores may be used, with one chromophore staining at one wavelength and another chromophore being visible at a different wavelength of incident light.
- the tissue targeting complex of the present invention has a targeting element that selectively interacts with ocular membranes. It is thus possible to selectively stain ocular membranes as the target area.
- Another object of the invention is therefore the use of the tissue-targeting complex according to the invention for staining of ocular tissue, in particular of ocular membranes.
- FIG. 1 shows a diagram with the graphical representation of the UVA / is spectroscopic measurement results of the BBG reference (blue) and BBG-MS solution (red) in concentrations of 0.005 to 0.08 mg / ml.
- FIG. 2 shows a diagram with the graphical application of the UV / Visspektroskopischen measurement results of 7a and b references (blue and red) and 7a and b-MS solution (purple and green) in concentrations of 0.005 to 0.16 mg / mL.
- Figure 3 is a graph showing the plot of the UVA / is spectroscopic measurements of the 7c and d references (blue and red) and 7c and d-MS solution (purple and green) in concentrations of 0.005 to 0.16 mg / mL.
- Figure 4 is a graph showing the plot of the UV / Visspektroskopischen measurement results of the ICG reference (blue) and ICG-MS solution (red) in concentrations of 0.005 to 0.04 mg / mL.
- the chemical shift data refer to the deuterated solvent signal as an internal standard.
- Measurements were taken using a lon-trap API Finnigan LCQ Deca type mass spectrometer.
- the substances to be determined were dissolved in a suitable solvent at a concentration of 1 mg / ml.
- the ionization was carried out by electrospray ionization.
- Thermo Finnigan Trace DSQ Dual-Stage Quadrupole
- the ionization of the samples was carried out by electron impact ionization (El).
- FT-IR spectra were recorded at room temperature using a Nicolet 6700 FT-IR spectrometer with LOT ATR attachment. The calibration of the wavenumber scale was carried out with a HeNe laser. The measurements were taken in a range of 4000-300 cm -1 .
- UVA / is spectroscopic images a two-beam spectrometer Specord® 210 Plus from Analytik Jena AG was used. The measurements were carried out at room temperature between 300 and 800 nm using a quartz glass cuvette of the layer thickness 1 cm. The evaluation took place with the help of the software WinAspect Plus of the company Analytik Jena AG.
- RP-HPLC measurements were taken using an Agilent 1200 with absorption and fluorescence detector.
- a binary eluent mixture of H 2 O and MeCN with 0.1% trifluoroacetic acid was used. The measurements were by gradient elution over a period of 10 min. from 5:95 to 95: 5.
- the solid is initially introduced into 200 g of polyphosphoric acid and heated to 140 ° C. for 2 h. After cooling to room temperature, the viscous reaction mixture is poured into 1 L of ice-water and extracted three times with 400 mL dichloromethane each time. After concentrating the organic phase under reduced pressure and column chromatographic purification over silica gel (hexane: ethyl acetate [7: 1]), the product 3 can be isolated.
- ILM model substrate similar to the ILM was used to enhance the binding ability of known dyes and staining complexes of the invention testing. It has been found that silk granules are well suited as ILM model substrate.
- UVA / is measurements of Brilliant Blue G (BBG), Compounds 7a-d, and indocyanine green (ICG) were performed at various concentrations both before and after treatment with model substrate. The aim of these measurements is a comparison of the binding strength of the dyes with each other. The results are listed below and are each shown in the figures 1 to 4 as a diagram.
- Phosphate buffered saline (PBS) with physiological pH of 7.4 was used to prepare the stock dye solutions at a concentration of 5 mg / mL. Due to the poor solubility of ICG in saline solutions, double distilled water was used. The concentrations are in
- Table 2 UV / Vis spectroscopic measurements of the BBG reference and BBG model substrate (MS) solution in concentrations of 0.005 to 0.08 mg / mL
- the anthraquinone dyes 7a-d according to the invention were also tested for their binding strength to the model substrate. Due to the lower absorption maximum, compared to the known BBG, 6 concentrations of 0.005 mg / mL to 0.16 mg / mL were measured in this case.
- Figures 2 and 3 show the graphical plots of the UVA / is spectroscopic measurement results.
- FIGS. 2 and 3 clearly show the very good bonds of the anthraquinone dyes 7b-d to the model substrate. Since the anthraquinone dyes have two absorption maxima, the graphics show two reference straight lines and two sample straight lines. The absorption maxima are at 588 nm and 632-635 nm. The reference absorption maxima are well above those of the model substrate treated values. Higher concentrations could not be recorded due to the high absorption of the reference. Table 3 shows the ratios of the A max values of the MS samples in relation to the corresponding references. The exact measurement results of the UVA is spectroscopic investigations are shown in Tables 4 to 7. As the length of the alkyl radicals increases, the interaction of the dyes with the model substrate increases.
- Table 3 UVA-spectroscopic measurement results of the 7-references and 7-MS solution in concentrations of 0.005 to 0.16 mg / mL
- UVA is spectroscopic measurements of the 7b references and 7b MS solutions in mg / mL concentration
- Indocyanine green is one of the most important dyes in chromovitrectomy, especially in the field of "ILM peeling."
- the dye poses some problems and handling difficulties, although it has been used for a long time for the staining of the membrana limitans interna and epiretinal membranes, could Studies, show numerous disadvantages of the dye.
- the low stability under the influence of light is also a serious problem when working with the dye.
- ICG can not be used and measured in phosphate buffered saline as this will precipitate the compound. For this reason, the subsequent measurements had to be carried out in double-distilled water, since measurements in buffer solution showed only settling of the dye after centrifuging.
- the graphically plotted UVA / is measurement results are shown in FIG.
- ICG also showed some problems in the present measurements. While the dye hardly showed any absorption up to a concentration of 0.02 mg / mL, at a concentration of 0.04 mg / mL, indocyanine green already has an absorption of 3.5822 and thus the maximum possible measured value. A higher concentration could not be recorded due to the excessive absorption and thus inaccurate measurement.
- the A max values of the reference and the model substrate dye solution could be put into proportion and resulted in positive bonds of the dye to the model substrate, but the results are very variable due to the low concentration in the error range inferior. The reason for this could be weak absorption at low concentrations and decomposition by light. During the measuring method, a complete exclusion of light influence could not be guaranteed.
- Table 8 UV / Vis spectroscopic measurements of the ICG reference and ICG-MS solution in concentrations of 0.005 to 0.04 mg / mL
- reaction was carried out analogously to the synthesis of 1,4-difluoroanthraquinone (1). After purification by column chromatography, the successful synthesis of compound 14 by 1 H-NMR, 13C-NMR and IR spectroscopy, as well as elemental analysis in low yields of about 20% could be detected. In the following, the modification with N, N-dimethylaminopropylamine (4) to the difunctionalized product 1, 4-bis ((3- (dimethylamino) propyl) amino) -6-methylanthraquinone (15) was carried out (Scheme 2). After purification by column chromatography of the product mixture, compound 15 could be clearly detected by means of 1 H-NMR spectroscopy. The fluorine-contiguous protons produce a singlet in this case, too, upon successful reaction to dye 15.
- N '- (((anthraquinone-1, 4-diyl) bis (azanediyl)) bis (propane-3,1-diyl)) bis (N, N-dimethyldecane-1-amine) bromide ( 7c) additional polymeric structures should be synthesized.
- Polymers in applications in the body prevent diffusion into deeper cell layers and thereby prevent toxic effects.
- polyvinylamine (PVA) was used as a polymeric base structure.
- the attachment to a polymeric structure was realized by the free fluorine atom of compound 21 via the primary amines of polyvinylamine (PVA).
- PVA polyvinylamine
- the reaction is carried out in THF / H 2 0 with traces of triethylamine to prevent a possible protonation of the amino groups.
- the resulting polymer is then blue due to the polymer-analogous attachment to 21 via the amine.
- the reaction scheme is shown below.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17157280.3A EP3363465A1 (de) | 2017-02-21 | 2017-02-21 | Membranfärbekomplex |
PCT/EP2018/054320 WO2018153944A1 (de) | 2017-02-21 | 2018-02-21 | Gewebe-targetingkomplex |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3585444A1 true EP3585444A1 (de) | 2020-01-01 |
Family
ID=58158856
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17157280.3A Pending EP3363465A1 (de) | 2017-02-21 | 2017-02-21 | Membranfärbekomplex |
EP18705171.9A Pending EP3585444A1 (de) | 2017-02-21 | 2018-02-21 | Gewebe-targetingkomplex |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17157280.3A Pending EP3363465A1 (de) | 2017-02-21 | 2017-02-21 | Membranfärbekomplex |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230181768A1 (de) |
EP (2) | EP3363465A1 (de) |
CN (1) | CN110536704B (de) |
WO (1) | WO2018153944A1 (de) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008030925A2 (en) * | 2006-09-06 | 2008-03-13 | The Regents Of The University Of California | Antimicrobial colorants |
EP2371395A1 (de) * | 2010-04-01 | 2011-10-05 | Medical Technology Transfer Holding B.V. | Farbzusammensetzung |
-
2017
- 2017-02-21 EP EP17157280.3A patent/EP3363465A1/de active Pending
-
2018
- 2018-02-21 EP EP18705171.9A patent/EP3585444A1/de active Pending
- 2018-02-21 WO PCT/EP2018/054320 patent/WO2018153944A1/de unknown
- 2018-02-21 CN CN201880025959.7A patent/CN110536704B/zh active Active
- 2018-02-21 US US16/487,233 patent/US20230181768A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230181768A1 (en) | 2023-06-15 |
EP3363465A1 (de) | 2018-08-22 |
WO2018153944A1 (de) | 2018-08-30 |
CN110536704B (zh) | 2022-09-27 |
CN110536704A (zh) | 2019-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2576699B1 (de) | Naphthocyanine als kontrastmittel | |
EP0209875B1 (de) | Resorufin-Derivate sowie Verfahren zu deren Herstellung | |
EP1040168B1 (de) | Neue farbstoff-polysaccharid-konjugate und deren verwendung als diagnostikum | |
EP3461815B1 (de) | Neue poly-sulfonierte fluoreszenz-farbstoffe | |
WO1993010189A1 (de) | Neue pentacyclische verbindungen und ihre verwendung als absorptions- oder fluoreszenzfarbstoffe | |
EP1809340B1 (de) | Stöchiometrisch definierte farbstoffmarkierte substanzen zur messung der glomerulären filtrationsrate | |
DE60208784T2 (de) | Clathrat von azithromycin-hydrat mit 1,2-propylenglykol, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung | |
DE69921151T2 (de) | Fluorszierende marker | |
DE3033895C2 (de) | ||
EP3585444A1 (de) | Gewebe-targetingkomplex | |
DE112020001265T5 (de) | Kristalline form e von bulleyaconitin a, verfahren zu seiner herstellung und anwendung davon | |
DE112020001275T5 (de) | Bulleyaconitin d kristall, verfahren zu seiner herstellung und seine verwendung | |
DE60221420T2 (de) | Trennung von regioisomeren von metallphthalocyaninen | |
DE1213734B (de) | Verfahren zur Sensibilisierung photographischer Halogensilberemulsionen mit Merocyaninen | |
DE1667874C3 (de) | Haarfärbemittel | |
DE2603046C2 (de) | 4'α- und 4'β-Amino-4'-desoxy-oleandrine, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Präparate | |
EP0849265A1 (de) | Neue polymorphe Form von Doxazosin-Mesylat (Form II) | |
DE1795731A1 (de) | Verfahren zur herstellung neuer antibiotisch wirksamer verbindungen | |
DE144634C (de) | ||
DE3442861A1 (de) | 4-(n-ethyl, n-2'-hydroxyethyl)-amino-1-(2"-hydroxyethyl)-amino-2-nitro-benzol und mittel zur faerbung von haaren | |
EP3820524B1 (de) | Hypericin-pvp komplex mit hohem hypericinanteil | |
EP0873365B1 (de) | Neue aromatische amin-cellulosederivate und verfahren zu deren herstellung | |
DE2401368C2 (de) | Photographische Silberhalogenidemulsion | |
WO2021148633A1 (de) | Komplex aus 7-deacetylforskolin und pvp | |
DE695982C (de) | Verfahren zur Sensibilisierung von Halogensilberembstoffen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190917 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231018 |